MCID: HYP043
MIFTS: 47

Hyperandrogenism malady

Categories: Endocrine diseases

Aliases & Classifications for Hyperandrogenism

Aliases & Descriptions for Hyperandrogenism:

Name: Hyperandrogenism 12 52 42 14 69
Hyperandrogenization Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11613
MeSH 42 D017588
SNOMED-CT 64 237793004
UMLS 69 C0206081

Summaries for Hyperandrogenism

MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to adrenal adenoma and mullerian aplasia and hyperandrogenism. An important gene associated with Hyperandrogenism is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and mTOR signaling pathway (KEGG). The drugs Estradiol and Metformin have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and immune system

Wikipedia : 71 Hyperandrogenism, also known as androgen excess, is a medical condition characterized by excessive... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
id Related Disease Score Top Affiliating Genes
1 adrenal adenoma 29.6 IGF1 INS POMC SHBG
2 mullerian aplasia and hyperandrogenism 12.2
3 hyperandrogenism due to cortisone reductase deficiency 11.8
4 hair-an syndrome 11.7
5 polycystic ovary syndrome 11.3
6 glucocorticoid resistance 11.0
7 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 10.9
8 diabetes mellitus, insulin-resistant, with acanthosis nigricans 10.7
9 mayer-rokitansky-kuster-hauser syndrome 10.7
10 cortisone reductase deficiency 1 10.7
11 cortisone reductase deficiency 2 10.7
12 cortisone reductase deficiency 10.7
13 brachyolmia 4 with mild epiphyseal and metaphyseal changes 10.7
14 testotoxicosis 10.7
15 obesity 10.4
16 seow najjar syndrome 10.3 IGF1 INS
17 cleft lip palate-tetraphocomelia 10.3 CYP21A2 POMC
18 distal monosomy 14q 10.3 CYP21A2 POMC
19 hyperlipoproteinemia type iii 10.3 INS POMC
20 vaginal adenoma 10.2 IGF1 POMC
21 acanthosis nigricans 10.2
22 congenital tricuspid stenosis 10.2 POMC PRL
23 anovulation 10.2
24 paroxysmal nonkinesigenic dyskinesia 2 10.2 IGFBP1 INS
25 wheat allergy 10.2 POMC PRL
26 intellectual disability-developmental delay-contractures syndrome 10.2 INS INSR
27 pancreatic colloid cystadenoma 10.2 POMC PRL
28 basal ganglia cerebrovascular disease 10.2 INS POMC SHBG
29 intraventricular meningioma 10.2 SHBG WNT4
30 glomangiomyoma 10.2 INS PRL SHBG
31 merkel cell carcinoma 10.2 INS POMC PRL
32 endometriosis 10.2 GNRH1 PRL
33 diabetes mellitus, insulin-dependent, 2 10.2 IGFBP1 INS SHBG
34 fatty liver disease 10.2 INS POMC PRL
35 posterior uveal melanoma 10.2 CYP21A2 INS POMC
36 neurogenic arthropathy 10.2 IGF1 INS POMC
37 diverticulitis 10.2 GNRH1 PRL
38 nonparalytic poliomyelitis 10.1 POMC PRL
39 caudal regression syndrome 10.1 IGF1 POMC PRL
40 bone benign neoplasm 10.1 IGF1 POMC PRL
41 chondroma 10.1 IGF1 INS POMC
42 necrobiosis lipoidica 10.1 IGF1 PRL SHBG
43 critical congenital heart disease 10.1 GNRH1 IGF1
44 rheumatic encephalitis 10.1 IGF1 POMC PRL
45 mucopolysaccharidosis type vi 10.1 IGF1 POMC PRL
46 immune system organ benign neoplasm 10.1 IGF1 POMC PRL
47 cockayne syndrome type i 10.1 INS PRL
48 cold-induced sweating syndrome 2 10.1 IGF1 POMC PRL
49 endocrine organ benign neoplasm 10.1 IGF1 POMC PRL
50 deafness, autosomal recessive 29 10.1 CYP17A1 CYP21A2

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.7 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.7 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 CYP21A2 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.7 INSR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.7 IGF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.7 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.7 INSR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.7 CYP21A2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.7 SHBG
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.7 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.7 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.7 CYP21A2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.7 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.7 CYP21A2 IGF1 INSR SHBG
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.7 IGF1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.7 INSR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.7 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.7 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.7 IGF1

MGI Mouse Phenotypes related to Hyperandrogenism:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.02 CYP19A1 GNRH1 IGF1 IGFBP1 INS INSR
2 endocrine/exocrine gland MP:0005379 10.01 INS INSR POMC PRL WNT4 CYP19A1
3 integument MP:0010771 9.87 CYP19A1 GNRH1 IGF1 INS POMC PRL
4 adipose tissue MP:0005375 9.83 CYP19A1 IGF1 INS INSR POMC
5 liver/biliary system MP:0005370 9.8 CYP19A1 GNRH1 IGFBP1 INS INSR POMC
6 nervous system MP:0003631 9.76 INS INSR CYP19A1 GNRH1 IGF1 POMC
7 renal/urinary system MP:0005367 9.5 CYP19A1 GNRH1 IGF1 INS INSR POMC
8 reproductive system MP:0005389 9.23 CYP17A1 CYP19A1 GNRH1 IGF1 INS INSR

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757 53477783
2
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
3
Drospirenone Approved Phase 4 67392-87-4 68873
4
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
5
Ethinyl Estradiol Approved Phase 4,Phase 2 57-63-6 5991
6
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
10
Liraglutide Approved Phase 4 204656-20-2
11
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
12
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
13
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
Resveratrol Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0, 955365-80-7 24856436 445154
16
Enclomiphene Investigational Phase 4,Phase 3,Phase 2 15690-57-0
17 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Estradiol valerate Phase 4,Phase 2 979-32-8
19
Cyproterone Phase 4 2098-66-0 5284537
20 Analgesics Phase 4,Phase 3,Phase 1
21 diuretics Phase 4,Phase 2
22 Natriuretic Agents Phase 4,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3
24 Contraceptive Agents Phase 4,Phase 2
25 Contraceptive Agents, Male Phase 4
26 Contraceptives, Oral Phase 4,Phase 2
27 Contraceptives, Oral, Combined Phase 4,Phase 2
28 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
29 Hemostatics Phase 4
30 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Androgen Antagonists Phase 4,Phase 2
33 Androgens Phase 4,Phase 3,Phase 2,Phase 1
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1
35 Diuretics, Potassium Sparing Phase 4,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
38 Drospirenone and ethinyl estradiol combination Phase 4
39 Estradiol 17 beta-cypionate Phase 4,Phase 2
40 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Estradiol 3-benzoate Phase 4,Phase 2
42 Estrogen Antagonists Phase 4,Phase 3,Phase 2
43 Estrogens Phase 4,Phase 3,Phase 2
44 Platelet Aggregation Inhibitors Phase 4,Phase 3
45 Polyestradiol phosphate Phase 4,Phase 2
46 Protective Agents Phase 4,Phase 3
47 Incretins Phase 4
48 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 106)
id Name Status NCT ID Phase
1 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4
2 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
3 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4
4 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4
5 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
6 Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. Completed NCT01896492 Phase 4
7 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
8 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
9 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
10 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4
11 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4
12 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4
13 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Recruiting NCT02766803 Phase 4
14 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Recruiting NCT01721915 Phase 4
15 Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Unknown status NCT01782911 Phase 3
16 Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study Unknown status NCT02133755 Phase 3
17 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3
18 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3
19 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3
20 The Adrenal Contribution to Androgen Production in Girls During Puberty Completed NCT01062568 Phase 3
21 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3
22 Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Completed NCT01961336 Phase 3
23 Obesity in Children and Adolescents: Associated Risks and Early Intervention Completed NCT01677923 Phase 3
24 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Not yet recruiting NCT03135301 Phase 3
25 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2
26 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women Completed NCT00704912 Phase 2
27 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2
28 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2
29 Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients Completed NCT02562664 Phase 2
30 Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2
31 Acupuncture or Metformin for Insulin Resistance in Women With PCOS Recruiting NCT02647827 Phase 2
32 Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome Recruiting NCT02644304 Phase 2
33 Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant Enrolling by invitation NCT02523898 Phase 2
34 Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome Not yet recruiting NCT03152591 Phase 2
35 Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome Completed NCT01457209 Phase 1
36 Time Course of Waking Versus Sleep-associated Luteinizing Hormone (LH) Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia Recruiting NCT00929006 Phase 1
37 Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Recruiting NCT01428089 Phase 1
38 Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006) Active, not recruiting NCT01602679 Phase 1
39 Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Terminated NCT01489319 Phase 1
40 Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425
41 Meal Timing on Glucose and Hyperandrogenism in PCOS Women Unknown status NCT01711476
42 Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome Unknown status NCT00784615
43 Metabolic Disorders in Polycystic Ovarian Syndrome Unknown status NCT00172523
44 The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome Unknown status NCT02126592
45 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome Unknown status NCT00665171
46 Long Acting GnRH Antagonist in PCOS Women Undergoing IVF Unknown status NCT02084940
47 Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine Unknown status NCT01116167
48 The Role of Insulin Resistance in PCOS Unknown status NCT00173043
49 Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age Unknown status NCT01826357
50 THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS Unknown status NCT01735799

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

MalaCards organs/tissues related to Hyperandrogenism:

39
Ovary, Skin, Testes, Bone, Pituitary, Prostate, Heart

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 624)
id Title Authors Year
1
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. ( 28089571 )
2017
2
Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. ( 26890011 )
2016
3
The 2015 Pediatric Endocrine Society Ethics Symposium: Controversies Regarding 'Gender Verification' of Elite Female Athletes - Sex Testing to Hyperandrogenism. ( 26918844 )
2016
4
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. ( 27459230 )
2016
5
Ethics of Regulating Competition for Women with Hyperandrogenism. ( 26832978 )
2016
6
Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage In Normal Weight Polycystic Ovary Syndrome Women. ( 27571186 )
2016
7
Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome. ( 27336356 )
2016
8
Adrenal Hyperandrogenism and Polycystic Ovary Syndrome. ( 27510480 )
2016
9
Hyperandrogenism rule no longer in play at Rio Olympics. ( 27503334 )
2016
10
A novel insulin receptor mutation in an adolescent with acanthosis nigricans and hyperandrogenism. ( 27505086 )
2016
11
The Relationship Between Hearing Thresholds and Hyperandrogenism in Polycystic Ovary Syndrome. ( 27846196 )
2016
12
Postmenopausal hyperandrogenism: the under-recognized value of inhibins. ( 27278937 )
2016
13
Metformin for women with hyperandrogenic anovulation. ( 26906093 )
2016
14
Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. ( 27179108 )
2016
15
Synchronous Ileal Neuroendocrine Tumor and Ovarian Steroid Cell Tumor Present in a Female With Hyperandrogenism. ( 27167674 )
2016
16
Ovarian Leydig cell hyperplasia as a rare cause of hair loss in a postmenopausal female patient: a case report and diagnostic approach toward postmenopausal hyperandrogenism. ( 26950172 )
2016
17
Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism. ( 27060006 )
2016
18
Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. ( 27756332 )
2016
19
Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective. ( 26964728 )
2016
20
Reply: Metformin for women with hyperandrogenic anovulation. ( 26906091 )
2016
21
Hyperandrogenism Decreases GRP78 Protein Level and Glucose Uptake in Human Endometrial Stromal Cells. ( 26614265 )
2016
22
A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans. ( 27746646 )
2016
23
Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. ( 26951881 )
2016
24
Gestational Hyperandrogenism in Developmental Programming. ( 27967205 )
2016
25
Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. ( 27259815 )
2016
26
Hyperandrogenism secondary to Leydig ovarian tumor. ( 25712320 )
2015
27
Evidence-based approach to cutaneous hyperandrogenism in women. ( 26138647 )
2015
28
Manifestation of Hyperandrogenism in the Continuous Light Exposure-Induced PCOS Rat Model. ( 26064969 )
2015
29
Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess. ( 25558892 )
2015
30
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS). ( 26322372 )
2015
31
Effect of hyperandrogenism on ovarian function. ( 25767140 )
2015
32
Identification of differentially expressed microRNAs in the ovary of polycystic ovary syndrome with hyperandrogenism and insulin resistance. ( 25591557 )
2015
33
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( 26491824 )
2015
34
Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. ( 26243032 )
2015
35
Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. ( 25417943 )
2015
36
Women with hyperandrogenism in elite sports: scientific and ethical rationales for regulating. ( 25587809 )
2015
37
Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. ( 25585504 )
2015
38
Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome. ( 26298265 )
2015
39
Peripheral Insulin Resistance in Obese Girls with Hyperandrogenism is Related to Oxidative Phosphorylation and Elevated Serum Free Fatty Acids. ( 25714677 )
2015
40
Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. ( 25610004 )
2015
41
Hormonal Evaluation of Hyperandrogenism in Women. ( 26670974 )
2015
42
Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome. ( 25637475 )
2015
43
Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. ( 25675386 )
2015
44
Hyperandrogenism-Insulin Resistance-Acanthosis Nigricans Syndrome. ( 26229697 )
2015
45
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women. ( 26199450 )
2015
46
Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism. ( 26089623 )
2015
47
Medical and ethical concerns regarding women with hyperandrogenism and elite sport. ( 25587808 )
2015
48
Transcutaneous electrical acupoint stimulation alleviates the hyperandrogenism of polycystic ovarian syndrome rats by regulating the expression of P450arom and CTGF in the ovaries. ( 26221326 )
2015
49
Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. ( 25711494 )
2015
50
The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. ( 25535503 )
2014

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 12.35 IGF1 INS INSR PRL
2
Show member pathways
12.2 IGF1 INS INSR WNT4
3 12.17 CYP19A1 IGFBP1 INS INSR
4
Show member pathways
11.92 IGF1 INS INSR
5
Show member pathways
11.85 IGF1 INS INSR
6 11.67 IGF1 INS INSR
7 11.64 IGF1 INS WNT4
8 11.6 CYP21A2 HSD3B2 POMC
9
Show member pathways
11.3 CYP17A1 CYP19A1 CYP21A2 HSD3B2 POMC
10
Show member pathways
11.28 CYP17A1 CYP19A1 HSD3B2
11
Show member pathways
11.26 CYP17A1 CYP19A1 CYP21A2 HSD3B2
12 11.2 INS INSR PRL
13 11.04 INS INSR
14 11 IGF1 INS INSR
15 10.88 IGF1 IGFBP1
16
Show member pathways
10.87 CYP17A1 CYP21A2
17 10.8 CYP17A1 CYP19A1 HSD3B2 IGF1 INS INSR
18 10.78 GNRH1 SHBG

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 GNRH1 IGF1 IGFBP1 INS POMC WNT4
2 extracellular region GO:0005576 9.23 GNRH1 IGF1 IGFBP1 INS POMC PRL
3 endosome lumen GO:0031904 8.96 INS PRL

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 IGF1 IGFBP1 INS PRL
2 positive regulation of cell migration GO:0030335 9.78 IGF1 INS INSR
3 positive regulation of MAPK cascade GO:0043410 9.72 IGF1 INS INSR
4 insulin receptor signaling pathway GO:0008286 9.71 IGFBP1 INS INSR
5 positive regulation of DNA replication GO:0045740 9.65 IGF1 INS INSR
6 positive regulation of glucose import GO:0046326 9.63 IGF1 INS INSR
7 activation of protein kinase B activity GO:0032148 9.61 IGF1 INS INSR
8 regulation of multicellular organism growth GO:0040014 9.6 IGF1 PRL
9 sex differentiation GO:0007548 9.59 CYP17A1 WNT4
10 female gonad development GO:0008585 9.58 CYP19A1 WNT4
11 adrenal gland development GO:0030325 9.58 INSR WNT4
12 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS INSR
13 male sex determination GO:0030238 9.57 GNRH1 INSR
14 ovulation cycle GO:0042698 9.56 GNRH1 PRL
15 sterol metabolic process GO:0016125 9.54 CYP17A1 CYP19A1 CYP21A2
16 positive regulation of respiratory burst GO:0060267 9.51 INS INSR
17 positive regulation of glycogen biosynthetic process GO:0045725 9.5 IGF1 INS INSR
18 mineralocorticoid biosynthetic process GO:0006705 9.49 CYP21A2 HSD3B2
19 steroid biosynthetic process GO:0006694 9.46 CYP17A1 CYP19A1 CYP21A2 HSD3B2
20 positive regulation of glycolytic process GO:0045821 9.43 IGF1 INS INSR
21 androgen biosynthetic process GO:0006702 9.13 CYP17A1 HSD3B2 WNT4
22 glucocorticoid biosynthetic process GO:0006704 8.8 CYP17A1 CYP21A2 HSD3B2

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.61 CYP17A1 CYP19A1 CYP21A2
2 heme binding GO:0020037 9.58 CYP17A1 CYP19A1 CYP21A2
3 steroid binding GO:0005496 9.46 CYP21A2 SHBG
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.43 CYP17A1 CYP19A1 CYP21A2
5 insulin-like growth factor I binding GO:0031994 9.37 IGFBP1 INSR
6 steroid hydroxylase activity GO:0008395 9.32 CYP19A1 CYP21A2
7 insulin-like growth factor II binding GO:0031995 9.16 IGFBP1 INSR
8 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS INSR
9 hormone activity GO:0005179 9.02 GNRH1 IGF1 INS POMC PRL

Sources for Hyperandrogenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....